drugset / Trial / NCT03101254
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation The interventions involved in this study are: * LY3022855 * Vemurafenib * Cobimetinib
Timeline
- Start
- 2017-06-06
- Primary completion
- 2020-10-21
- Completion
- 2020-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobimetinib | Small molecule | 60 mg | Oral |
| Subject | LY3022855 | Monoclonal antibody | 50 mg | Intravenous |
| Subject | LY3022855 | Monoclonal antibody | 75 mg | Intravenous |
| Subject | LY3022855 | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Vemurafenib | Small molecule | 960 mg | Oral |